Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777430 | 1.00 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDELANECTSG | |
| SCHEMBL13923766 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDELANETYMS | |
| SCHEMBL1535917 | 0.79 | ACHE (0.56) | ALDH1A1KDM4EHPGDGAAPBRM1 | |
| SCHEMBL17056471 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDTYMSGAA | |
| SCHEMBL20190017 | 0.76 | HSD17B1 (0.44) | ALDH1A1KDM4EHPGDGAAPBRM1 | |
| SCHEMBL22025585 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDTYMSGAA | |
| SCHEMBL386061 | 0.76 | SLC22A8 (0.49) | ALDH1A1KDM4EHPGDGAAPBRM1 | |
| SCHEMBL11243020 | 0.76 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDGAAPBRM1 | |
| SCHEMBL6958079 | 0.76 | KDM4E (0.67) | ALDH1A1KDM4EHPGDGAAHSD17B1 | |
| SCHEMBL836908 | 0.73 | KDM4E (0.69) | ALDH1A1KDM4EHPGDTYMSGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| EP-3853209-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2021-07-28 | — | — | EP | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2020058945-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2020-03-26 | — | — | WO | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| US-8378118-B2 | Pyrazole-based thyroid receptor compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120202816-A1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS, LTD. (IN) | 2012-08-09 | — | — | US | disclosed |
| US-8143424-B2 | Thyroid like compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2012-03-27 | — | — | US | disclosed |
| EP-2061766-B1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2010-08-18 | — | — | EP | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
| EP-2061766-A2 | NOVEL COMPOUNDS | Torrent Pharmaceuticals Ltd (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008149379-A2 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202816-A1 | NOVEL COMPOUNDS | TSHR, THRB, GPR119 | ALDH1A1 1664/4885KDM4E 3112/4885HPGD 4251/4885 |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | ALDH1A1 86/4885KDM4E 2775/4885HPGD 1098/4885 |
| US-20100168110-A1 | Novel Compounds | TSHR, THRB, GPR119 | ALDH1A1 1664/4885KDM4E 3112/4885HPGD 4251/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | ALDH1A1 86/4885KDM4E 2775/4885HPGD 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.